SOLY - Soliton, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
14.30
-1.45 (-9.21%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close15.75
Open15.62
Bid14.26 x 1200
Ask14.50 x 900
Day's Range14.24 - 16.01
52 Week Range4.12 - 29.00
Volume493,177
Avg. Volume1,333,093
Market Cap214.002M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.66
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire4 days ago

    Soliton Announces Long-Term Cellulite Trial Results to be Presented at The Aesthetics Show on July 11-14, 2019

    HOUSTON, June 12, 2019 /PRNewswire/ -- Soliton, Inc. (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that Dr. Omer Ibrahim of Chicago Cosmetic Surgery and Dermatology will present 26-week data from its completed proof-of-concept cellulite clinical trial at The Aesthetics Show dermatology conference in Las Vegas, Nevada, to be held July 11-14, 2019.

  • PR Newswire5 days ago

    Soliton Confirms Conference Call to Discuss Recently Announced Significant Discovery and FDA Clearance for Today at 4:30 PM ET

    HOUSTON, June 11, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), will conduct a webcast to discuss its recent announcements regarding its significant discovery of acoustic subcision and its 510(k) clearance for its acoustic shockwave RAP device. Interested parties can access the live webcast on the Company's website under the Investors section at http://ir.soliton.com.

  • PR Newswire11 days ago

    Soliton Announces Conference Call to Discuss Recently Announced Significant Discovery and FDA Clearance

    HOUSTON, June 5, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), will conduct a webcast to discuss its recent announcements regarding its significant discovery of acoustic subcision and its 510(k) clearance for its acoustic shockwave RAP device. Interested parties can access the live webcast on the Company's website under the Investors section at http://ir.soliton.com.

  • Soliton Announces Significant Discovery of Acoustic Subcision for Treatment of Cellulite
    PR Newswire12 days ago

    Soliton Announces Significant Discovery of Acoustic Subcision for Treatment of Cellulite

    RAP technology combines selective disruption of fibrotic structures with production of new collagen in single non-invasive procedure HOUSTON , June 4, 2019 /PRNewswire/ -- Soliton, Inc., (NASDAQ: SOLY) ...

  • Why Soliton's Shares Went on a Roller Coaster Ride Today
    Motley Fool17 days ago

    Why Soliton's Shares Went on a Roller Coaster Ride Today

    The company is riding high following FDA clearance for its tattoo removal medical device.

  • Soliton Tattoo Removal Device: SOLY Stock Skyrockets on FDA Approval
    InvestorPlace18 days ago

    Soliton Tattoo Removal Device: SOLY Stock Skyrockets on FDA Approval

    Approval from the U.S. Food and Drug Administration (FDA) for a Soliton tattoo removal device has SOLY stock on the rise Wednesday.Source: Shutterstock Soliton (NASDAQ:SOLY) says that this approval from the FDA will allow it to move out of the R&D segment and into commercialization of its product. The Soliton tattoo removal device works by sending an acoustic pulse into the skin to disperse the ink of a tattoo. The company calls it the Rapid Acoustic Pulse, or RAP, tattoo removal device.There are several benefits to using the Soliton tattoo removal device over other methods. Among these is the fact that the device is able to remove tattoos without causing much pain. It also doesn't leave damaging effects, such as bruising.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnother benefit of the Soliton tattoo removal device is how quickly is works. The company says that customers seeking to have tattoos removed can do so in two or three office visits. This is much quicker than the 10 or more office visits that other methods require. * 7 Stocks to Buy for June "Taking into consideration that the tattoo removal industry is estimated to grow to approximately $4.8 billion annually by 2023, we are eager to further our commercialization plans and move towards our launch and revenue generation as early the first half of 2020," Soliton says in a press release.SOLY stock was up 33% as of noon Wednesday and is up 191% since the start of the year. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy for June * 7 Stocks to Buy From One of America's Best Pension Funds * 4 Consumer Staples Stocks for Both Income and Growth As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Soliton Tattoo Removal Device: SOLY Stock Skyrockets on FDA Approval appeared first on InvestorPlace.

  • Bloomberg18 days ago

    Medtech Firm Extends 300% Surge on Cellulite, Tattoo Device Hope

    (Bloomberg) -- Small-cap medical devicemaker Soliton Inc. shares extended their record week after U.S. regulators approved its tattoo removal device on Tuesday.

  • Stock Market Tumbles At Open, Breaks Below Key Levels
    Investor's Business Daily18 days ago

    Stock Market Tumbles At Open, Breaks Below Key Levels

    The stock market correction hit hit new lows with Dow stocks Apple and Intel down. Canada Goose and Soliton were big movers.

  • TheStreet.com18 days ago

    Soliton Soars a Second Day After FDA Approves Tattoo Removal Device

    were soaring for a second day in trading Wednesday after the Food and Drug Administration approved its Rapid Acoustic Pulse (RAP) device for tattoo removal. The device is an accessory for its black ink tattoo removal system for the arms, legs and torso. "Receiving clearance from the FDA, while inline with our expectations, is nonetheless gratifying and validating, representing a bedrock for the commercialization plan of our RAP technology," said Chris Capelli, president, CEO and co-founder of Soliton.

  • PR Newswire18 days ago

    Soliton to Initiate Pivotal Cellulite Trial after Positive Proof-of-Concept Trial Results with 20-47% Improvement in Cellulite Severity Score

    Justifies proceeding with Pivotal Trial. HOUSTON, May 29, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced its decision to move forward with a pivotal trial in cellulite after positive data from its proof of concept clinical trial for the reduction of cellulite (the "POC Trial") confirmed. In a single 20-minute, non-invasive treatment, the Rapid Acoustic Pulse (RAP) device was applied to the surface of the patients' skin.  The treatments required no anesthesia, caused no bruising, swelling or bleeding, and were evaluated as relatively painless by the trial participants, none of whom experienced any post-treatment discomfort or downtime.  The data was originally presented at the SCALE (Symposium for Cosmetic Advances and Laser Education) conference in Nashville, Tennessee, by Dr. Elizabeth Tanzi on May 11, 2019.

  • Dow Jones Futures Fall: Stock Market Correction Poised To Hit New Lows
    Investor's Business Daily18 days ago

    Dow Jones Futures Fall: Stock Market Correction Poised To Hit New Lows

    Futures signaled new stock market correction lows. Software has been a bright spot, but Workday fell late on earnings. Soliton kept surging on the FDA's OK of its tattoo removal device.

  • Companies to Watch: Canada Goose misses, Intel unveils new chips, Soliton soars on FDA approval
    Yahoo Finance18 days ago

    Companies to Watch: Canada Goose misses, Intel unveils new chips, Soliton soars on FDA approval

    Canada Goose, Intel, Soliton, Bed Bath & Beyond and Wynn Resorts are the companies to watch.

  • CNBC19 days ago

    Stocks making the biggest moves after hours: Workday, Inovio and more

    Shares of Workday W seesawed in extended trading on Tuesday — jumping as much as 2% before falling more than 1% — after the software company reported better-than-expected first-quarter earnings. Inovio Pharmaceuticals INO stock plummeted as much as 11% after news broke that Astrazeneca, a pharmaceutical company, will discontinue its research collaborations with the biotech company. Refinitiv consensus estimates had projected earnings of 49 cents per share and net sales of $479.5 million.

  • Benzinga19 days ago

    Soliton Rallies On FDA Approval For Tattoo Removal Device

    Medical device company Soliton Inc. (NASDAQ: SOLY) has received FDA 510(k) approval for its acoustic wave device for dermal tattoo clearing. Soliton has developed a breakthrough science for tattoo removal using rapid acoustic pulse, or RAP, technology. The FDA approved the RAP tattoo removal device, and the application will now move to a substantive review.

  • PR Newswire19 days ago

    Soliton Receives FDA 510(k) Clearance of its Acoustic Shockwave RAP Device

    HOUSTON , May 28, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed ...

  • Benzingalast month

    Soliton Responds To Blog Calling It A 'PR Machine'

    Medical device company Soliton, Inc. (NASDAQ: SOLY) reacted Friday to a blog post calling the firm a "PR machine" and addressed whether it can achieve Food and Drug Administration clearance to market its new Rapid Acoustic Pulse technology. The Seeking Alpha post by White Diamond Research said Soliton has issued 17 press releases since March with little real news following a Reg A+ IPO in Feburary.

  • PR Newswirelast month

    Soliton Provides FDA Update and Addresses Recent Anonymous Article

    HOUSTON, May 17, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today provided an update on its application for FDA clearance and addressed a recent anonymous article published on SeekingAlpha.com.

  • PR Newswirelast month

    Soliton's RAP Device Able to Penetrate Vacuole Shielding; Targets $4 Billion Potential Tattoo Removal Market

    HOUSTON, May 16, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today discussed the use of its Rapid Acoustic Pulse Technology for the removal of tattoos using the capability of the device to clear the vacuoles that result from the use of a laser to ablate tattoo ink.

  • PR Newswirelast month

    Biotech Brief: Most Recent Technological Advancements Pushing U.S. Medical Device Market to New Levels

    PALM BEACH, Florida, May 14, 2019 /PRNewswire/ -- The U.S. is a global leader in technology. The U.S. is also historically where innovation is always at the forefront… so it is no surprise that the U.S. Medical Device market… a marriage of technology and innovation… is making the U.S. the global leader in medical devices. Typically, the purpose of a medical device is not achieved by pharmacological, immunological, or metabolic means… it is a technological solution.   The medical device industry relies on several industries where the United States holds a competitive advantage, including microelectronics, telecommunications, instrumentation, biotechnology, and software development.

  • PR Newswirelast month

    Soliton Receives Approval for New Patent for its Acoustic Shockwave Technology

    Clinical trials for tattoo removals have demonstrated that using the Company's RAP device, in conjunction with a Q-Switched laser, allows for multiple passes of laser treatment in a single treatment session.  The current standard of care for tattoo removal is to use a Q-Switched laser to ablate the tattoo ink particles into pieces small enough for the body's natural processes to remove them. Independent studies have shown this standard treatment requires on average ten or more office visits to achieve acceptable results.

  • Soliton to be Featured on Yahoo Finance's 'The First Trade' Show on May 13, 2019 to Discuss Cellulite Trial Results
    PR Newswirelast month

    Soliton to be Featured on Yahoo Finance's 'The First Trade' Show on May 13, 2019 to Discuss Cellulite Trial Results

    HOUSTON, May 9, 2019 /PRNewswire/ -- Soliton, Inc. (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today reaffirmed that its Executive Chairman, Walter Klemp, will give a live interview on Yahoo Finance on Monday, May 13, 2019. As the Company has previously announced, data from its recently completed proof-of-concept clinical trial to study the safety and efficacy of a new version of its acoustic shockwave device for the treatment of moderate to severe cellulite will be presented to the scientific community at a national aesthetics conference, SCALE 2019 on May 11, 2019.

  • Soliton Announces Completion of New Replaceable Cartridge to Target Cellulite Reduction
    PR Newswire2 months ago

    Soliton Announces Completion of New Replaceable Cartridge to Target Cellulite Reduction

    HOUSTON, May 1, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that its manufacturing partner has delivered the first single-use cartridges capable of delivering the therapy targeting cellulite reduction. The cartridge attaches to the treatment head and is designed to be used for a single patient cellulite treatment and then replaced.  The cartridge is capable of delivering higher-powered acoustic pulses at greater depths than the Company's tattoo removal cartridge, and both cartridges can be used with the same higher-powered pulse generating console, creating a true platform technology with a range of potential uses in the practitioner's office.  Neither the cartridge nor the device has been cleared by the FDA.

  • Soliton Announces Global Partner Completes Second Generation RAP Device to More Effectively Target Cellulite Reduction
    PR Newswire2 months ago

    Soliton Announces Global Partner Completes Second Generation RAP Device to More Effectively Target Cellulite Reduction

    HOUSTON, April 23, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that its development team has completed final testing of the Company's second generation rapid acoustic pulse ("Gen 2 RAP") device at Sanmina, Inc., the Company's global manufacturing partner.

  • Fighting cellulite and removing tattoos with sound waves
    Yahoo Finance Videolast month

    Fighting cellulite and removing tattoos with sound waves

    The global market to combat cellulite is huge. It's expected to reach nearly $1.4 billion dollars by 2026, and one company is hoping to capitalize. Soliton is out with a new rapid acoustic pulse technology that reduces cellulite and helps to remove tattoos. The company just announced "cellulite clinical trial results with 20-47% improvement in cellulite severity score.” Yahoo Finance's Alexis Christoforous, Jared Blikre and Brian Sozzi are joined by the Executive Chairman and co-founder of Soliton, Wally Klemp.

  • Global market to combat cellulite to reach $1.4B by 2026
    Yahoo Finance Videolast month

    Global market to combat cellulite to reach $1.4B by 2026

    Soliton technology is looking to cash in on the rise of the cellulite removal market, which is set to be worth $1.4 billion dollars by 2026. Yahoo Finance talks to Wally Klemp, the Executive Chairman of Soliton, about the the company's new acoustic shockwave technology that reduces cellulite.